Term
| how mnay cases of HIV per year |
|
Definition
|
|
Term
_% of new HIV cases are diagnosed
_ of these will get right care |
|
Definition
|
|
Term
whcih gender gets HIV more?
which is 1/4 cases? |
|
Definition
|
|
Term
| majority of new HIV cases are with what ppl |
|
Definition
|
|
Term
| what are 2 risk factros for HIV being a male |
|
Definition
high risk hetero sex
IV drug abuse |
|
|
Term
| women risk factors for HIV? |
|
Definition
high risk heter sex- 80%
iv drug abuse |
|
|
Term
| what 2 races get HIV more |
|
Definition
|
|
Term
|
Definition
| primary infection, clinical latency, AIDs |
|
|
Term
_% have symtpoms of primary infeciton
when does thisinfection occur?
what are the symptoms like? |
|
Definition
50
2-4 weeks after exposure
flu-like |
|
|
Term
| AIDS presents secondary to |
|
Definition
|
|
Term
|
Definition
|
|
Term
| what is an AIDS defining condition-3 |
|
Definition
| opportunsitic infection, HIV wasting/CNS disease, cancers |
|
|
Term
untreated ppl progress to AIDS in
_ yrs |
|
Definition
|
|
Term
| who should be tested for HIV-6 |
|
Definition
| shared needles, STDS, prostitute, hemophilia, unprotected sex with a risk group, anyone who requests |
|
|
Term
what is the screening test used?
(sensitiv) |
|
Definition
|
|
Term
| when can you tests for HIV |
|
Definition
| 45-60 days post infection |
|
|
Term
what is the confirmation test?
(specific) |
|
Definition
|
|
Term
| what is a screenig test that can be done at home |
|
Definition
|
|
Term
| what patients are reccomended for ART |
|
Definition
|
|
Term
| initiation of treatment is strongly indicated for- 4 |
|
Definition
| AIDS defining illness, preggo, HIV nephropathy, co-infected Hep B |
|
|
Term
| factors to consider prior to treatment-3 |
|
Definition
-degree of immunodef
-disease progression (viral burden
-patient attitude |
|
|
Term
|
Definition
|
|
Term
| why is the curernt NRTI duo the back bone of choice- 2 |
|
Definition
ease of admin
safety profile |
|
|
Term
| when picking NRTIs, avoid- |
|
Definition
| 2 analogs of same nucleosides |
|
|
Term
| which alternative NRTI doesnt have greater side affects |
|
Definition
|
|
Term
what are the protease sparing meds
-this means have less _ symtpom, more _ & _ |
|
Definition
|
|
Term
|
Definition
1st trimester preggo or risk of preggo
psychiatric |
|
|
Term
| which med is a alt to efavirenz with less side affects? |
|
Definition
|
|
Term
| rilpivirine can only be used in pateints with |
|
Definition
|
|
Term
which NNRTI causes hepatic toxicity?
so avoid in patinets with? |
|
Definition
Nevirapine;
F CD4>250, M CD4>400 |
|
|
Term
| which NNRTI has hypersensitivity issues |
|
Definition
|
|
Term
unique properties of:
atanzavir -2 |
|
Definition
| 1x daily, asmyp hyperbilirubinemia |
|
|
Term
unique properties of:
darunavir- 4 |
|
Definition
| rash, sulfa moiety, drug hepatitis, hyperglycemia, |
|
|
Term
which PI is preferred in preggo?
side affects |
|
Definition
lopinavirasuea, hyperlipidemia
n |
|
|
Term
which PI is a prodrug?
side affects? |
|
Definition
fosamprenavir
rascardiovasc, hyperlipidsh, |
|
|
Term
what is the integrase strand transfer inhibitor?
a strength of this drug? |
|
Definition
raltegravir
few side affects |
|
|
Term
CCR5 antagonist drug
need to perfrom what test fr this? |
|
Definition
maraviroc
tropism (need CCR5-tropic) |
|
|
Term
| patient adherence help with longevitiy- they need to take _ % of dose? |
|
Definition
|
|
Term
| how can pharmacists prevent early discontinuation of therapy |
|
Definition
|
|
Term
| what reflects the progression of HIV disease? |
|
Definition
|
|
Term
| how often should viral load be measured |
|
Definition
|
|
Term
| what reflects the current immune status |
|
Definition
|
|
Term
| how often should CD4 count be measured? |
|
Definition
|
|
Term
| what is the preferred method for resistnace testing? |
|
Definition
|
|
Term
which resistance test is more expensive?
when do you use this one? |
|
Definition
phenotype
in combo with genotype in complex ppl |
|
|
Term
| what classifies patient as virologic failure? - 2 |
|
Definition
don't meet viral load goals
have increase in viral load |
|
|
Term
| if virologic failure what needs to be done? |
|
Definition
| change meds- even all of them |
|
|
Term
| specific therapeutic endpoints for viral load- 2 |
|
Definition
<400 copies at 24 weeks
<48 copies at 48 weeks |
|
|
Term
| what are therapuetic endpoints for CD$ count |
|
Definition
| should rincrease 100 cells/yr |
|
|
Term
|
Definition
| few- they are glucuronidated |
|
|
Term
| didanosine should not be used with? |
|
Definition
|
|
Term
| which are the NNRTI 3A4 inducers |
|
Definition
|
|
Term
| which are the NNRTI 3A4 substrate |
|
Definition
|
|
Term
|
Definition
|
|
Term
PIs should not be given with what specific antihyperlipidemic agents?
what meds CAN these antihyperlipid be used with? |
|
Definition
simvastatin, lovastatin
efavirenz, nevirapine |
|
|
Term
| what med ineracts with PIs and NNRTIS |
|
Definition
|
|
Term
| what meds shouldnt be used with PIs and efavirenz-2 |
|
Definition
|
|
Term
| with PIS want to avoid also using |
|
Definition
| St. John's wart, alkaloids |
|
|
Term
Raltegravir is a _ substrate
this may interact with what 2 meds |
|
Definition
UGT1A1
atanzavir, gemfibrozil |
|
|
Term
| maravioc is a _ substrate |
|
Definition
|
|
Term
| what is the 3A4 inhibitor med |
|
Definition
|
|
Term
|
Definition
lactic acidosis
hepatomegaly |
|
|
Term
|
Definition
insulin resistance
lipodystrophy
osteoporosis
dyslipidemia |
|
|
